Details of the Drug

General Information of Drug (ID: DMX2OMJ)

Drug Name
Immune globulin
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Approved [1]
Bone marrow transplantation QB63.6 Approved [2]
Immune System disease 4A01-4B41 Approved [2]
Immunodeficiency 4A00-4A85 Approved [2]
Virus infection 1A24-1D9Z Approved [2]
Nervous system paraneoplastic or autoimmune disorders 8E4A.1 Phase 3 [3]
Pediatric cancer 2A00-2F9Z Phase 2 [4]
Bacillus anthracis infection 1G40 Phase 1 [5]
⏷ Show the Full List of Indication(s)
Cross-matching ID
TTD ID
D01OWB
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 Clinical pipeline report, company report or official report of Octapharma.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT00110708) Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT00448253) Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum. U.S. National Institutes of Health.